Dantrolene-13C3

Dantrolene-13C3 is the 13C3 labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.

1185234-99-4

F 368-13C3

12352005

Glutathione Reductase (GR) ; Isotope-Labeled Compounds

Isotope-Labeled Compounds

Metabolic Enzyme/Protease; Others

COVID-19-immunoregulation

Inflammation/Immunology; Neurological Disease

https://www.medchemexpress.com/dantrolene-13c3.html

99.0

10 mM in DMSO

O=[13C](N[13C]1=O)[13CH2]N1/N=C/C2=CC=C(C3=CC=C(C=C3)[N+]([O-])=O)O2

C11 13C3H10N4O5

317.23

[1]F Zhao, et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem. 2001 Apr 27;276 (17) :13810-6.|[2]Murat Sentürk, et al. Dantrolene inhibits human erythrocyte glutathione reductase. Biol Pharm Bull. 2008 Nov;31 (11) :2036-9.|[3]Shigeki Kobayashi, et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol. 2009 May 26;53 (21) :1993-2005.|[4]W J Meyler, et al. The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration. Eur J Pharmacol. 1979 Feb 1;53 (4) :335-42.|[5]Xi Chen, et al. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener. 2011 Nov 25;6:81.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

Isotope-Labeled Compounds